2453 Results for "

Human antibodies

" in MedChemExpress (MCE) Product Catalog:
Products (2453)

2453 Results for "Human antibodies" in MCE Product Catalog:

63
63 Publications Verification
Cat. No.: HY-P9906
CAS No.: 216974-75-3
Synonyms: Anti-Human VEGF, Humanized Antibody
Bevacizumab (Anti-Human VEGF, Humanized Antibody) is a humanized monoclonal antibody against VEGF-A and an angiogenesis inhibitor. Bevacizumab blocks the interaction between VEGF-A and VEGF receptors. Bevacizumab possesses immunomodulatory properties. Bevacizumab can be used in research on metastatic colorectal cancer, metastatic breast cancer, and non-small cell lung cancer .
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-P9905
CAS No.: 205923-56-4
Synonyms: C225; IMC-C225
Research Areas:  

Cancer

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-P9917
CAS No.: 375823-41-9
Synonyms: Anti-Human IL6R, Humanized Antibody; RG-1569; rhPM-1
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-P9903
CAS No.: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106

Target:  

PD-1/PD-L1

Research Areas:  

Infection Cancer

Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-P99001

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Human IgG1 kappa, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1 kappa antibody .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-P9908
CAS No.: 331731-18-1
Synonyms: Anti-Human TNF-alpha, Human Antibody; ABBV-3373 Antibody

Target:  

TNF Receptor Bacterial

Research Areas:  

Inflammation/Immunology Cancer

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-108847
CAS No.: 185243-69-0
Purity:  99.20%

Target:  

TNF Receptor Bacterial

Research Areas:  

Inflammation/Immunology Cancer

Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-P99003

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Human IgG4 (S228P) kappa, Isotype Control, a human-derived monoclonal antibody, is an isotype control for human IgG4κ antibody.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-P9927A
CAS No.: 1229022-83-6

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-P9927
CAS No.: 1229022-83-6
Synonyms: AIN457

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-P9915
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414

Target:  

CD38 ADC Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-P9915A
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody (PBS)

Target:  

ADC Antibodies CD38

Research Areas:  

Cancer

Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-138298
CAS No.: 1826843-81-5
Purity:  98.90%
Synonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
Research Areas:  

Cancer

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-138298A
CAS No.: 1826843-81-5
Purity:  99.58%
Synonyms: T-DXd; DS-8201; DS-8201a
Research Areas:  

Cancer

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730
CAS No.: 1537032-82-8
Synonyms: Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-108730A
CAS No.: 1537032-82-8
Purity:  96.02%

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-K0214

MCE Protein G Agarose, a 4% highly cross-linked agarose reagent coupled with recombinant Protein G, effectively purifies mammalian monoclonal and polyclonal antibodies, such as human IgG3 and rat IgG2a.

loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P9926
CAS No.: 1190264-60-8
Synonyms: REGN-668; SAR-231893

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P99974
Synonyms: Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007

Research Areas:  

Cancer

Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and solid tumors. (The product specifications below only indicate the effective content of Paditaxel, the actual albumin quality depends on the batch; the ratio of each ingredient in this product is Paditaxel: albumin -1:7~1:11) .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P9919
CAS No.: 1428935-60-7
Synonyms: MEDI 4736

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
loading...
    loading...